Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Halozyme posts record revenue in 2022, eyes growth opportunities

Halozyme's strong financial performance in 2022 and positive revenue guidance for 2023 reflect a robust growth trajectory.
While facing integration challenges from acquisitions and potential competition, the company's strategic priorities and market engagement remain strong.
Exploring new collaborations, advancing product development, and maintaining a competitive edge present key opportunities for Halozyme.
Overall, Halozyme's proactive approach to growth and market dynamics positions it well for future success in the biopharmaceutical industry.

Halozyme reports robust Q1 earnings, poised for continued growth

Halozyme's strong Q1 performance and robust pipeline position them for continued revenue growth and leadership in subcutaneous drug delivery.
Challenges include regulatory impacts and legal uncertainties, but opportunities in new agreements, partnerships, and investments offer avenues for future growth.
Overall, Halozyme's strategic focus on innovation and revenue diversification bodes well for their long-term success and financial stability.

Halozyme reports robust Q2 growth, eyes new partnerships for revenue

Halozyme's Q2 2023 earnings call showcased strong financial performance, innovative product developments, and a positive outlook for revenue growth. The company's focus on expanding partnerships, maintaining revenue durability, and strategic capital allocation positions it well for future success in the biopharmaceutical market.

Halozyme excels in Q3, raises guidance, eyes market expansion

Halozyme's Q3 performance reflects financial strength and operational resilience, supported by strategic partnerships and revenue growth.
The company's focus on shareholder value through accelerated buybacks and commitment to innovation positions them for sustained success.
While challenges like market competition exist, Halozyme's opportunities in market expansion and revenue growth paint a positive outlook for the future.

Halozyme posts record earnings, eyes strategic growth opportunities ahead

Halozyme's strong financial results and positive outlook for 2024 position the company for continued growth and value creation.
Addressing challenges around market adoption and reimbursement processes will be key to unlocking the full potential of subcutaneous products.
Strategic partnerships, new product launches, and a focus on shareholder value enhancement underscore Halozyme's commitment to sustainable growth.

Halozyme reports robust Q1 growth, navigates biosimilar challenges

Halozyme's Q1 2024 performance demonstrated strong financial growth driven by royalties and milestone payments, supported by operational achievements and strategic capital allocation.
While facing challenges such as biosimilar competition and partnership complexities, the company remains well-positioned to capitalize on opportunities in subcutaneous delivery preferences and market expansion.
Overall, Halozyme's focus on revenue diversification, partnership expansion, and operational excellence sets a positive trajectory for sustained growth and resilience in the biopharmaceutical sector.

Halozyme posts strong Q3 results, raises guidance amid growth opportunities

Halozyme Therapeutics reported a stellar Q3 performance with significant revenue growth and raised guidance across key financial metrics. The company's partnerships, product portfolio, and strong financial position underscore its growth potential and market resilience. Halozyme is well-positioned to capitalize on opportunities for expansion and innovation in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mike DiFiore - Evercore Corinne Jenkins - Goldman Sachs Jessica Fye - JPM Chase Anita Dushyanth - Berenberg Capital Markets Operator Good afternoon. My name is Emma, and I will be your conference operator today.

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2022 Results - Earnings Call Transcript

First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record Quarterly Royalties in the First Quarter of $69.6 million, Representing 89% Growth over First Quarter 2021 Reiterate 2022 Revenue Guidance of $530 Million to $560 Million, Representing 20-26% Growth over Reported 2021 Revenue Reiterate 2022 GAAP Operating Income Guidance of $350 million to $380 million, Representing 27%-38% Growth over 2021 GAAP Operating Income SAN DIEGO , May 10, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today reported financial results for the first quarter ended March 31, 2022 and provided an update on its recent corporate activities and outlook. "We started 2022 strongly, achieving record royalty revenues with significant growth that was in-line with our guidance for 2022, and with the signing of a new ENHANZE collaboration and licensing agreement with Chugai Pharmaceutical," said Dr. Helen Torley, president and chief executive officer of Halozyme.

Halozyme Reports First Quarter 2022 Results

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. KSF is seeking to determine whether this consideration and the process that led to

ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Antares Pharma, Inc. - ATRS

SAN DIEGO , May 3, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m.

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction, shareholders of Antares will receive only $5.60 in cash for each share of Antares that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclassl

ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS

Antares Pharma

SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement").

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins.

Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?

After inking a deal to acquire small-cap auto-injector specialist Antares Pharma Inc. ( ATRS , Financial) for about $960 million, San Diego-based Halozyme Therapeutics Inc. ( HALO , Financial) may not be done beefing up its portfolio.

Halozyme Open to More Acquisitions After Antares Deal

Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Antares Pharma, Inc. ("Antares") (NASDAQ: ATRS) regarding possible breaches of fiduciary duties and other violations of law related to Antares' agreement to be acquired by Halozyme Therapeutics, Inc. (NASDAQ: HALO). Under the terms of the agreement, Antares' shareholders will receive $5.60 in cash for each share of Antares common stock they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-antares-pharma-inc.To...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Antares Pharma, Inc. Buyout

AbbVie

Crinetics Pharmaceuticals Inc

Sierra Oncology

Turning Point Therapeutics

Check out these biotech stocks with exciting developments today.

Best Biotech Stocks To Buy Now? 5 To Know

Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

Halozyme (HALO) to Acquire Antares for Auto Injector Platform

NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "Company") (NASDAQ: ATRS), in connection with the proposed acquisition of the Company by Halozyme Therapeutics, Inc. (NASDAQ: HALO) via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $5.60 in cash for each share of Antares common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.

Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-.

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme will pay $5.60 a share in cash for Antares.

Antares Pharma Stock Soars After $960 Million Halozyme Buyout

Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeutics Inc. HALO, +0.58% in a cash deal valued at $960 million. Halozyme's stock was still inactive ahead of the open.

Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m.

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.

Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition

Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.

Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Halozyme Therapeutics (HALO) Up 11.4% Since Last Earnings Report: Can It Continue?

SAN DIEGO , March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusive access to Halozyme's ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for an undisclosed target.

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology

- Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration - - Biologics License Application on track to be submitted by argenx to U.S. Food and Drug Administration by end of 2022 - SAN DIEGO , March 22, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that data from argenx's Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod (1000mg efgartigimod-PH20) for the treatment of generalized myasthenia gravis (gMG) achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to VYVGART® (efgartigimod alfa-fcab) intravenous (IV) formulation in gMG patients. Based on these results, argenx has stated it plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the end of 2022.

Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis

SAN DIEGO , March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an accomplished executive with over 25 years of global strategic, mergers & acquisitions and business transformation expertise.

Halozyme Appoints Moni Miyashita to Board of Directors

I was drawn to Halozyme due to its business model that is devoid of in-house drug development. Halozyme reformulates many blockbuster drugs that provided them with significant milestones and royalty.

Halozyme: Steady Revenue Growth At A Reasonable Valuation

Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues

Halozyme Therapeutics, Inc.'s (HALO) CEO Helen Torley on Q4 2021 Results - Earnings Call Transcript

News for Halozyme Therapeutics Stock (HALO)